TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05240287

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Navicular Drop Test
Description: The researchers will measure the distance between the navicular tuberosity and the ground with a caliper with non-weight bearing in sitting. After that, the distance between the ground and the navicular tuberosity will be measured in standing while weight-bearing. The researchers will evaluate both sides and record the value in mm. According to Navicular Drop Test, the difference between weighted and unweighted measurements is considered normal (neutral) if it is between 5 and 9 mm, pronation (pes planus) if it is 10 mm or more, and supination (pes cavus) if it is 4 mm or less. In our study, individuals with a difference of 10 mm or more in both feet will be included in the pes planus, and individuals with a difference between 5-9 mm will be included in the control group.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Navicular Drop Test
Description: The researchers will measure the distance between the navicular tuberosity and the ground with a caliper with non-weight bearing in sitting. After that, the distance between the ground and the navicular tuberosity will be measured in standing while weight-bearing. The researchers will evaluate both sides and record the value in mm. According to Navicular Drop Test, the difference between weighted and unweighted measurements is considered normal (neutral) if it is between 5 and 9 mm, pronation (pes planus) if it is 10 mm or more, and supination (pes cavus) if it is 4 mm or less. In our study, individuals with a difference of 10 mm or more in both feet will be included in the pes planus, and individuals with a difference between 5-9 mm will be included in the control group.
Study: NCT06631053

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: velocity-based FIT (VBFIT)
Description: Participants will ambulate unilaterally using a shoe modified with a 5cm rocker-style stack and forearm crutches for the duration of the study.~All participants will complete two testing sessions prior to ULLS, one testing session at day 13, and two testing sessions at the end of the study. Those assigned to the exercise group will perform a both high-intensity resistance and aerobic exercise three times per week

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No Exercise
Description: Participants will ambulate unilaterally using a shoe modified with a 5cm rocker-style stack and forearm crutches for the duration of the study.~All participants will complete two testing sessions prior to ULLS, one testing session at day 13, and two testing sessions at the end of the study.
Study: NCT04393935

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pharmacy Delivered PrEP Intervention
Description: Men who are eligible and agree to the clinical screener will be provided with a pre-packaged kit of self-administered tests for HIV, rectal chlamydia, syphilis and gonorrhea and creatinine and directed back to the private area of the pharmacy to perform their screenings. Participants will be asked to return the screening tests to the pharmacy technician. The pharmacy technician will process/ interpret the results of the rapid HIV test first in case a treatment referral needs to be set up. Then s/he will process/interpret the results of a rapid rectal chlamydia, syphilis, gonorrhea and rapid finger prick creatinine test. HIV negative customers will be provided with their results and be given a 30-day prescription for PrEP, culturally appropriate PrEP counseling and a follow-up appointment with a PrEP prescribing physician. Participants will be contacted after 3 months to determine whether they continued PrEP use.
Study: NCT04921501

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Conventional 12-lead ECG
Description: This standard 12-lead ECG is defined on the HD ECG, from electrodes F13, G3, G14, H5, H15, H25 corresponding to the precordial electrodes. 4 limb electrodes will be added for the frontal leads. Thus, the HD and 12-lead ECGs will be obtained simultaneously.
Study: NCT06194201

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HRS9432
Description: Dosing frequency: intravenously once week

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Caspofungin Acetate for Injection
Description: Dosing frequency: D1 70mg，followed by 50mg intravenously once daily
Study: NCT06226415

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Rehabilitation therapy
Description: The study lasted 14d for each patient. During the treatment, All the participants were provided with the rehabilitation therapy, which included routine rehabilitation, cognitive training, swallowing function training and nutrition support.~Particularly, due to dysphagia, the patients enrolled might face difficulty in eating. For patients who were able to finish intake via mouth by compensatory means, the consistency, type, and size of food bolus was arranged. For those who cannot acquire sufficient nutrition through oral intake, the nasogastric tube feeding was provided.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Rehabilitation therapy
Description: The study lasted 14d for each patient. During the treatment, All the participants were provided with the rehabilitation therapy, which included routine rehabilitation, cognitive training, swallowing function training and nutrition support.~Particularly, due to dysphagia, the patients enrolled might face difficulty in eating. For patients who were able to finish intake via mouth by compensatory means, the consistency, type, and size of food bolus was arranged. For those who cannot acquire sufficient nutrition through oral intake, the nasogastric tube feeding was provided.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stellate ganglion block
Description: Based on the invention above, the patients in the observation group were provided with Stellate ganglion block, using 1.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g). The percutaneous approach via the paratracheal route was used for Stellate ganglion block. The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine Hydrochloride
Description: Based on the invention above, the patients in the observation group were provided with Stellate ganglion block, using 1.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g). The percutaneous approach via the paratracheal route was used for Stellate ganglion block. The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
Study: NCT06293287

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Subcutaneous enoxaparin sodium
Description: Subcutaneous enoxaparin sodium injections at a dose of 4000 Axa IU once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo (0.9% saline solution)
Study: NCT06321536

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Allogeneic Microbiota in Glycerol (9%) (AMG)
Description: Participants will receive an Emory-manufactured MT product, delivered as 250mL via rectal enema or an existing functioning feeding tube with the rate adjusted to participant tolerance. Participants will receive three doses over the first seven days of the study.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Allogeneic Microbiota in Glycerol (9%) (AMG)
Description: Participants will receive an Emory-manufactured MT product, delivered as 250mL via rectal enema or an existing functioning feeding tube with the rate adjusted to participant tolerance. Participants will receive three doses over the first seven days of the study.
Study: NCT04967001

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: PSMA PET
Description: 68Ga-PSMA PET

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: PSMA PET
Description: 68Ga-PSMA PET
Study: NCT04957082

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Culturally Targeted SARS-CoV-2 Communication
Description: SARS-CoV-2 video tutorial includes a one minute video based messaging adjunct meant to enact a culturally targeted framing of health information presented to African Americans.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: General SARS-CoV-2 Communication
Description: SARS-CoV-2 video tutorial is for general consumption and does not include culturally targeted information

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: General SARS-CoV-2 Communication
Description: SARS-CoV-2 video tutorial is for general consumption and does not include culturally targeted information
Study: NCT06137092

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Factor VIII, recombinant human with Fc fusion (rFVIII-Fc)
Description: rFVIII-Fc, IV, 50 units/kg/ single dose, cross-over

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Factor VIII, recombinant human with Fc fusion (rFVIII-Fc)
Description: rFVIII-Fc, IV, 50 units/kg/ single dose, cross-over
Study: NCT04873193

Intervention type: DEVICE
Group type: OTHER
Intervention: Leo device
Description: Children's respiratory flow and volume measurements will be continuously recorded using the Leo device during oscillometry and pneumotach procedures.
Study: NCT05062707

Intervention type: PROCEDURE
Intervention: Blood sampling
Description: Study measurements will be performed twice and consist of blood withdrawal and physical examination (weight, height, waist-hip ratio, and blood pressure).
Study: NCT06416982

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Perineal massage
Description: 2 minutes of perineal massage as described in arm/group descriptions.
Study: NCT05590221

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Relmacabtagene Autoleucel
Description: A single infusion of chimeric antigen receptor (CAR)-transduced autologous T cells

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Administered according to package insert
Study: NCT05809830

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LB-100 plus Doxorrubicin
Description: In Phase one the intervention will be LB-100 plus Doxorrubicin. The experimental arm in Phase II will also be LB-100 plus Doxorrubicin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin
Description: The control arm in Phase II will be Doxorrubicin alone
Study: NCT01092169

Intervention type: OTHER
Intervention: No intervention
Study: NCT04909112

Intervention type: OTHER
Group type: OTHER
Intervention: Evaluation of olfactory function
Description: Evaluation of olfactory function using olfactory detection thresholds

Intervention type: OTHER
Group type: OTHER
Intervention: Evaluation of olfactory function
Description: Evaluation of olfactory function using olfactory detection thresholds

Intervention type: OTHER
Group type: OTHER
Intervention: Evaluation of taste function
Description: Evaluation of taste function using taste detection thresholds

Intervention type: OTHER
Group type: OTHER
Intervention: Evaluation of taste function
Description: Evaluation of taste function using taste detection thresholds

Intervention type: OTHER
Group type: OTHER
Intervention: Evaluation of (intra-nasal and oral) trigeminal functions
Description: Evaluation of (intra-nasal and oral) trigeminal, interacting with olfactory and taste pathways, using odor and taste stimuli.

Intervention type: OTHER
Group type: OTHER
Intervention: Evaluation of (intra-nasal and oral) trigeminal functions
Description: Evaluation of (intra-nasal and oral) trigeminal, interacting with olfactory and taste pathways, using odor and taste stimuli.
Study: NCT05125809

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Setrusumab
Description: A fully human sclerostin neutralizing monoclonal antibody (mAb) administered once a month (QM) via intravenous (IV) infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Setrusumab
Description: A fully human sclerostin neutralizing monoclonal antibody (mAb) administered once a month (QM) via intravenous (IV) infusion

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Setrusumab
Description: A fully human sclerostin neutralizing monoclonal antibody (mAb) administered once a month (QM) via intravenous (IV) infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Setrusumab
Description: A fully human sclerostin neutralizing monoclonal antibody (mAb) administered once a month (QM) via intravenous (IV) infusion
Study: NCT06198777

Intervention type: DEVICE
Intervention: Magnetometer
Description: Inspection equipment for magnetocardiography
Study: NCT05590221

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Administered according to package insert
Study: NCT05012436

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YHD1119 75mg
Description: A single oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YHD1119 75mg
Description: A single oral dose
Study: NCT04805827

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin
Description: 1 tablet contains 600 mg Gabapentin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neurontin
Description: 2 capsule contains 2\*300 = 600 mg Gabapentin
Study: NCT05469204

Intervention type: DRUG
Group type: OTHER
Intervention: Midazolam oral solution
Description: 2 mg single-dose before and during estradiol treatment.

Intervention type: DRUG
Group type: OTHER
Intervention: Digoxin Oral Tablet
Description: 0.25 mg single-dose before and during estradiol treatment.

Intervention type: DRUG
Group type: OTHER
Intervention: Acetaminophen Oral Tablet
Description: 500 mg single-dose before and during estradiol treatment.

Intervention type: DRUG
Group type: OTHER
Intervention: Midazolam Injectable Solution
Description: 1 mg intravenous single-dose before and during estradiol treatment.
Study: NCT05982210

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Breathing Exercises and Manual Therapy of the Muscle Diaphragm and Ribs Protocol
Description: The intervention consists on applying a protocol based on five different exercises, compound by breathing exercises and manual therapy of the muscle diaphragm and the ribs, applied by a physiotherapist.
Study: NCT06222333

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Respiratory physiotherapy
Description: In this group of patients, in addition to routine analgesic treatment, triflow use and deep breathing training would be given by the physiotherapist. Patients in this group will do breathing exercises 8 hours a day, 10 times an hour.
Study: NCT05125809

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A 5% dextrose/glucose solution administered QM via IV infusion
Study: NCT06222333

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Conservative Treatment
Description: Patients in the control group will receive conservative treatment consisting of paracetamol and dexketoprofen.
Study: NCT05464784

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MN-001
Description: MN-001 is a novel, orally bioavailable small molecule compound

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: MN-001 placebo
Description: The placebo tablet is identical in appearance to the MN-001 tablet, and contains excipients of MN-001.
Study: NCT06379893

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Voltaren Gel 1% (diclofenac sodium) (US only)
Description: Participants in the US will use Volatren Gel containing 1% diclofenac sodium.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Voltaren Gel 1.16% (diclofenac diethylammonium) (EU only)
Description: Participants in the EU will use Volatren Gel containing 1.16% diclofenac diethylammonium.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Voltaren Gel 2.32% (diclofenac diethylammonium) (EU only)
Description: Participants in the EU will use Volatren Gel containing 2.32% diclofenac diethylammonium.
Study: NCT06391034

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hyperpolarized pyruvate +/-urea (13C/15N)
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hyperpolarized pyruvate +/-urea (13C/15N)
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hyperpolarized pyruvate +/-urea (13C/15N)
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hyperpolarized pyruvate +/-urea (13C/15N)
Description: Given IV

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Non-investigational Stereotactic body radiotherapy (SBRT)
Description: Stereotactic body radiotherapy given outside of this study

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Non-investigational Stereotactic body radiotherapy (SBRT)
Description: Stereotactic body radiotherapy given outside of this study

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radiotherapy (RT)
Description: Radiation therapy given outside of this study

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Multi-parametric magnetic resonance imaging (mpMRI)
Description: Imaging scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Multi-parametric magnetic resonance imaging (mpMRI)
Description: Imaging scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Multi-parametric magnetic resonance imaging (mpMRI)
Description: Imaging scan

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Multi-parametric magnetic resonance imaging (mpMRI)
Description: Imaging scan

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Non-interventional hormone therapy
Description: Therapy given outside of this study as part of standard of care

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Prostate Biopsy
Description: Biopsies may be taken from Trans-rectal ultrasound (TRUS) -visible lesion at the urologist's discretion
Study: NCT05235113

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tele-Exergame Platform
Description: Subjects will perform exercises remotely twice a week with tele-exergaming platform.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: No Tele-Exergame Platform
Description: Subjects will perform exercises in the home exercise twice a week without tele-exergaming platform.
Study: NCT06442189

Intervention type: DIETARY_SUPPLEMENT
Intervention: Mediterranean Diet
Description: The aim was to evaluate the effects of the application of a Mediterranean diet on the reproductive and metabolic parameters in the 3rd month of patients with a body mass index of 25 and more who were treated in our clinic due to a diagnosis of PCOS.
Study: NCT06310122

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Extracorporeal shockwave therapy
Description: Devices used to improve foot function pain and gait pattern~Patients will be placed in prone position, therapist locate the point of maximum tenderness. treatment area will be prepared with coupling gel to minimize the loss of shockwave therapy at the interface between applicator tip and skin. Each patient will receive 2000 impulses ,3 bar energy,15mm depth applicator at frequency (10 HZ) per session / week for 4 weeks

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ultrasound
Description: Devices used to improve foot function pain and gait pattern~Participants in the study group will be treated with 5 minutes of therapeutic ultrasound at a frequency of 1 MHz and continuous current at a pulse intensity of 1.8 W/cm2 (when the sensitivity level was too high and the procedure hurt the patient, the therapist reduced the intensity . 3 sessions /week for 4 weeks

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ultrasound
Description: Devices used to improve foot function pain and gait pattern~Participants in the study group will be treated with 5 minutes of therapeutic ultrasound at a frequency of 1 MHz and continuous current at a pulse intensity of 1.8 W/cm2 (when the sensitivity level was too high and the procedure hurt the patient, the therapist reduced the intensity . 3 sessions /week for 4 weeks
Study: NCT05750030

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: FMT combined with Atezolizumab plus Bevacizumab
Description: Single FMT from patients with HCC who responded to PD-(L)1-based immunotherapy to patients with HCC who failed to achieve complete or partial response (according to mRECIST) to atezolizumab/bevacizumab. After single FMT, patients will continue to receive atezolizumab/bevacizumab every 21-days according to protocol.
Study: NCT04692337

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intra-operative Ommaya Reservoir placement
Description: An Ommaya reservoir is a small device implanted under the scalp that enables percutaneous access to cerebrospinal fluid.
Study: NCT06214143

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: T3011 high dose
Description: T3011 high dose： T3011 will be given intratumorally，Q2W； PD-1/PD-L1 inhibitor：Administered by intravenous infusion，3 mg/kg，Q2W

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: T3011 middle dose
Description: T3011 middle dose： T3011 will be given intratumorally，Q2W； PD-1/PD-L1 inhibitor：Administered by intravenous infusion，3 mg/kg，Q2W

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: T3011 low dose
Description: T3011 low dose： T3011 will be given intratumorally，Q2W； PD-1/PD-L1 inhibitor：Administered by intravenous infusion，3 mg/kg，Q2W
Study: NCT05716633

Intervention type: DIAGNOSTIC_TEST
Intervention: MRI
Description: Serial MRI scans will be performed starting at day 15 from date of pain. Subsequent scans will be performed at 5 days interval till the clinically significant encapsulation (for all the collections in an individual patient) is seen.
Study: NCT05335070

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temporo-masseteric Nerve Block
Description: Following lower third molar extraction under intravenous sedation, the patient will receive the TMNB local anesthetic nerve block using the standard dental local anesthetic, i.e,. 2% lidocaine with 1:100,000 epinephrine on the side/s of the lower wisdom molar (third molar) extraction/s
Study: NCT05453266

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Application of Tranexamic acid in arthroscopic irrigation solution
Description: Application of Tranexamic acid in arthroscopic irrigation solution

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: No application of Tranexamic acid in arthroscopic irrigation solution
Description: No application of Tranexamic acid in arthroscopic irrigation solution
Study: NCT04956289

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Viltolarsen
Description: Received during weekly intravenous infusions